BIO Wants Waxman/Hatch Reform Isolated From Generic Biologics
Executive Summary
BIO hopes that jurisdictional considerations will prevent the Senate Judiciary Committee's discussion of Waxman/Hatch revisions from becoming a forum for arguments over an FDA approval process for generic versions of biological products.
You may also be interested in...
FDA, USP Should Set Generic Biologics Standards, Sen. Hatch Proposes
Generic biologics should be a priority issue for the next FDA commissioner, Sen. Orrin Hatch (R-Utah) says
FDA, USP Should Set Generic Biologics Standards, Sen. Hatch Proposes
Generic biologics should be a priority issue for the next FDA commissioner, Sen. Orrin Hatch (R-Utah) says
BIO Brings Lawton In-House As VP-Reg Affairs/Counsel: PDUFA III Looms
Biotechnology Industry Organization VP-Regulatory Affairs Stephan Lawton will focus on the reauthorization of the Prescription Drug User Fee Act upon joining the association on Jan. 1, 2001.